ProCE Banner Activity

KEYNOTE-028: Antitumor Activity With Pembrolizumab in Patients With PD-L1-Positive Extensive-Stage SCLC

Slideset Download
Conference Coverage
In this phase Ib study, pembrolizumab demonstrated promising antitumor activity in SCLC with a 35% overall response rate and 25% of patients experiencing a partial response.

Released: June 01, 2015

Expiration: May 30, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation